[14]REGAN M M, FRANCIS P A, PAGANI O, et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapy for premenopausal women with HR+ HER2-negative breast cancer: results from TEXT and SOFT[J]. J Clin Oncol, 2018, 36(suppl 15): 503-503. [15]LAMBERTINI ...
[6] Lu YS, Mahidin EIBM, Azim H, et al. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. J Clin Oncol...
2019;37(5):423-438.Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N Engl J Med. 2020;383(26):2557-2570.Johnston SRD. Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. J Natl Cancer ...
[14]REGAN M M, FRANCIS P A, PAGANI O, et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapy for premenopausal women with HR+ HER2-negative breast cancer: results from TEXT and ...
[7].Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 2017;28:2420–8.* 本文由阿斯利康提供支持，仅供医疗专业人士参考 审批编号：CN-106964 有效期至：2023-12-6 *此...
[2] Li Y, Abudureheiyimu N, Mo H, et al. In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China. Front Oncol....
22、Aditya Bardia,et al.Datopotamab deruxtecan(Dato-DXd)vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive,HER2-negative(HR+/HER2–)breast cancer(BC):Primary results from the randomised Phase 3 TROPION-Breast01 trial.2023 ESMO Abstract LBA11. ...
日前,复旦大学附属肿瘤医院邵志敏教授团队在 Nature Genetics 发表研究报告「Molecular classification of hormone receptor-positive HER2-negative breast cancer」,公布了 HR+/HER2-乳腺癌的复旦分型。通过多组学分析,将 HR+/HER2-乳腺癌进一步细分为 4 种亚型。这 4 种亚型在生物学行为、临床特征上存在一定差异,相应...
2023年9月,我带领的团队在Nature Genetics发表了“Molecular classification of hormone receptor-positive HER2-negative breast cancer”的文章,公布了HR+/HER2-乳腺癌的复旦分型[17]。我们团队通过建立579例HR+/HER2-乳腺癌患者的大规模多组学队列,确定了以下四种分子亚型:经典管腔型、免疫原性型、增殖型、受体酪氨酸...
[8] Turner NC, et al.Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer:results from the Phase III CAPItello-291 trial.2022 SABCS.GS3-04. ...